

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/533,420
		Filing Date	04-29-2005
		First Named Inventor	Hongming Chen
		Art Unit	1743
		Examiner Name	Gakh, Yelena
Sheet	5	of	8
		Attorney Docket Number	TP15020USPCT1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOWTELL, D., "Options available-from start to finish-for obtaining expression data by microarray", Nat Genet, 21 (1 Supp), pgs. 25-32 (1999)	
		BERGLUND et al., "Screening chemical and physical stability of drug substances", J. Pharm. Biomed. Analysis, 1990, V. 8, No8-12, pp. 639-643	
		BEVAN et al., "A High Throughput Screening Method for the Determination of Aqueous Drug Solubility...", Anal. Chem., 2000, v. 72, pp. 1781-1787	
		BYRN et al., Pharmaceutical solids: a strategic approach to regulatory considerations", Pharmaceutical Research, 1995, v. 12, No. 7, pp. 945-54	
		CHANDLER et al., "High-throughput Screening Techniques for Pre-formulation: Salt Selection and Polymorph Studies", Acta Cryst., 2002, A58, (Supplement) C9	
		CHAYEN et al., "Microbatch crystallization under oil-a new technique allowing many small-volume crystallization trials", J. of Crystal Growth, 122: pgs. 176-80 (1992)	
		COX et al., "An investigation of protein crystallization parameters using successive automated grid searches (SAGS)", J. of Crystal Growth, 90: pgs. 318-324 (1988)	
		CRAW et al., "Case based design for Tablet Formulation", proc. 4th Eur. Workshop on Case based Reasoning, pgs. 358-369 (1998)	
		CREESE, "Receptor Binding as a Primary Drug Screen", Neurotransmitter Receptor Binding, 2nd Ed., Ch. 9, pgs. 189-233 (1985)	
		ECKSTEIN et al., Unattended, Robotic Drug-Release Testing of Enterically Coated Aspirin", Anal. Chem., 58: pgs. 2316-2320 (1986)	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	6	of	8	Application Number	10/533,420
				Filing Date	04-29-2005
				First Named Inventor	Hongming Chen
				Art Unit	1743
				Examiner Name	Gakh, Yelena
				Attorney Docket Number	TP15020USPCT1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Food and Drug Administration, "International Conference on Harmonisation: Draft Guideline on Impurities..." Federal Register 62: pgs. 24302-09 (1997)	
		GARDNER, "Application of High-Throughput Technologies to Drug Substance and Drug Product Development", FOCAPD, 12 January 2002	
		GEORGE et al., "Automated dissolution testing of sustained release tablets", American Laboratory 20: pgs. 106-112 (1988)	
		GOLD et al., "Effects of Selective U.S.P. Talcs on Acetylsalicylic Acid Stability in Tablets", Journ. Pharm. Sci., 53(1), pgs. 52-54 (1964)	
		GORDON et al., "Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions", J. Med. Chem., 37(10), pgs. 1384-1401 (1994)	
		HILFIKER et al., Polymorphism - integrated approach from high-throughput screening to crystallization optimization", Journal of Thermal Analysis and Calorimetry, 2003, v. 73,	
		IYER et al., "Studies on Instantaneous release of Drug Compounds for Microfluidic High-throughput Screening Applications", Polymer Preprints: ACS, Division of Polymer Chemistr	
		KORNBLUM, ' Stability Studies of Small Solid Dosage Forms", Drug & Cosmetic Industry, 1970, v. 106, No. 4, pp. 141-146	
		LENCZEWSKI et al., "Automated Screening Method for Determining Optimum Preservative Systems...", Journal of AOAC International, 81: pgs 534-9 (1998)	
		LENNERNAS, "Human Intestinal Permeability", Journal of Pharm. Sci., 87: pgs. 403-410 (1998)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	7	of	8	Application Number	10/533,420
				Filing Date	04-29-2005
				First Named Inventor	Hongming Chen
				Art Unit	1743
				Examiner Name	Gakh, Yelena
				Attorney Docket Number	TP15020USPCT1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIPINSKI et al., "Aqueous Solubility in Discovery, Chemistry, and Assay Changes", Methods and Principles in Medicinal Chemistry, 2003, 18 (Drug Bioavailability), pp. 215-231	
		LIPINSKI et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery...", Advanced Drug Delivery, 2001, v. 46, pp. 3-26	
		LITTLECHILD et al., "Protein crystallization: magical or logical: can we establish some general rules?", J. of Physics, pgs. 111-118 (1991)	
		MARTIN et al., "Automation of Microtiter Plate-Chromogenic Substrate LAL Endotoxin Assay Method...", J. of Parenteral Science and Technology, 4: pgs. 61-6 (1986)	
		MC FARLAND et al., "Combinatorial approaches to materials discovery", Trends Biotechnol., 17(3): pgs. 107-115 (1999)	
		MEHTA, "Issues and approaches for improving the solubility and bioavailability of poorly water soluble compounds", Bulletin Technique Gattefosse, 1998, v. 91, pp. 65-72	
		MERE et al., "Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening", August 1999 DDT, 4(8), pgs. 363-369	
		MERRITT, A.T., "Uptake of new technology in lead optimization for drug discovery", 1998 DDT, 3(11), pgs. 505-510	
		MORELOCK et al., "Estimation and Correlation of Drug Water Solubility with Pharmacological Parameters Required for...", J. Pharm. Sci., 1994, v. 83, No. 7, pp. 498-52	
		PROMEGA, Inc., "Cell Titer 96 Aqueous One Solution Cell Proliferation Assay", 1996 Neural Notes, 11(3), 15	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.G./

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/533,420
		Filing Date	04-29-2005
		First Named Inventor	Hongming Chen
		Art Unit	1743
		Examiner Name	Gakh, Yelena
Sheet	8	of	8
		Attorney Docket Number	TPI5020USPCT1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SHARMA et al., "Pharmaceutical and Physical Properties of Paclitaxel (Taxol) Complexes with Cyclodextrins", J. Pharm. Sci., 84, 10, pgs. 1223-1230 (1995)	
		SONG et al., "Controlled release of U-86983 from double-layer biodegradable matrices: effect of additives...", J. Cont. Rel., 45(2), pgs. 177-192 (1997)	
		TAKAI et al., "Optimum Formulation of Griseofulvin/Hydroxypropyl Cellulose Solid Dispersions with Desirable...", Chem. Pharm. Bull., 32(5), pgs. 1942-7 (1984)	
		WANG et al., "A New Ultra-high Throughput Method for Characterizing...", Rapid Commun. in Mass Spectrom., 12, pgs. 1123-1129 (1998)	
		WARD et al., "Automatic preparation of protein crystals using laboratory robotics and automated visual inspection", J. of Crystal Growth, 90, pgs. 325-339 (1988)	
		"1998 ARES Meeting Wine Tasting" Online! XP002248070, Retrieved from the Internet: URL: http://www.aresnet.org/ARES/meetings_1998Wine.html retrieved on 7/15/2003	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.G./



Under the Espenwork Collection Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number 10/533,420
Filing Date 04-29-2005
First Named Inventor Hongming Chen
Art Unit 1743
Examiner Name Gakh, Yelena
Attorney Docket Number TPI5020USPCT1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	US-	3,899,011	08-12-1975	Curtiss	
	US-	5,859,703	01-12-1999	Aldridge et al.	
	US-	5,417,923	05-23-1995	Bojanic et al.	
	US-	4,399,687	08-23-1983	Collins	
	US-	5,843,767	12-01-1998	Beattie	
	US-	5,985,214	11-16-1999	Stylli et al.	
	US-	5,490,415	02-13-1996	Mak et al.	
	US-	5,503,843	04-02-1996	Santus et al.	
	US-	6,271,038	08-07-2001	Liu et al.	
	US-	6,296,673	10-02-2001	Santarsiero et al.	
	US-	4,808,705	02-28-1989	Ferris, R.	
	US-	5,746,982	05-05-1998	Saneil et al.	
	US-	2001/0016631	08-23-2001	Freitag et al.	
	US-	2001/0055775	12-27-2001	Schultz et al.	
	US-	2002/0023507	02-28-2002	Hajduk et al.	
	US-	2002/0029621	03-14-2002	Hajduk et al.	
	US-	2002/0032531	03-14-2002	Mansky et al.	
	US-	2002/0037647	03-28-200	Hwang et al.	
	US-	2002/0048610	04-25-2002	Cima et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	WO	94/11489	05-26-1994	BIOLOG, INC.		
	WO	96/06842	03-07-1996	PFIZER LIMITED		
	WO	96/16078	05-30-1996	PFIZER LIMITED		
	WO	99/08112	02-18-1999	SUPRATEK PHARMA INC.		
	WO	98/40159	09-17-1998	TREGA BIOSCIENCES, INC		
	WO	98/47613	10-29-1998	SYMXY TECHNOLOGIES		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	8
-------	---	----	---

Complete if Known

Application Number	10/533,420
Filing Date	04/29/2005
First Named Inventor	Hongming Chen
Art Unit	1743
Examiner Name	Gakh, Yelena
Attorney Docket Number	TP15020USPCT1

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 st
		Country Code* Number ** Kind Code* (if known)	MM-DD-YYYY			
		WO 98/52614	11-26-1998	BOARD OF TRUSTEES OF..		
		WO 99/04247	01-28-1999	SYMXX TECHNOLOGIES		
		WO 99/06814	02-11-1999	SARNOFF CORPORATION		
		WO 00/03240	01-20-2000	CETEK CORPORATION		
		WO 00/29987	05-25-2000	UNIV OF MARYLAND		
		WO 02/31477	04-18-2002	SYMXX TECHNOLOGIES		

Examiner
Signature

/Yelena Gakh/

Date	Cons
------	------

11/20/2008

*EXAMINER: Include if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Initial date copy of this form with next communication to applicant. ¹ Applicant's unit citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. ⁶ Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.G./